The price of Tilray Brands Inc (NASDAQ:TLRY) shares last traded on Wall Street fell -6.93% to $2.15.
TLRY stock price is now 16.00% away from the 50-day moving average and 6.00% away from the 200-day moving average. The market capitalization of the company currently stands at $1.60B.
With the price target of $3.90, Bernstein recently initiated with Mkt Perform rating for Tilray Brands Inc (NASDAQ: TLRY). On July 29, 2022, The Benchmark Company Downgraded its previous ‘Hold’ rating to ‘Sell’ on the stock keeping its target price maintained at $3, while ‘Canaccord Genuity’ rates the stock as ‘Buy’
In other news, FALTISCHEK DENISE M, Chief Strategy Officer bought 10,000 shares of the company’s stock on Jan 17 ’24. The stock was bought for $20,500 at an average price of $2.05. Upon completion of the transaction, the Chief Strategy Officer now directly owns 293,269 shares in the company, valued at $0.63 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 16 ’24, Global General Counsel Gendel Mitchell bought 7,200 shares of the business’s stock. A total of $14,256 was incurred on buying the stock at an average price of $1.98. This leaves the insider owning 195,796 shares of the company worth $0.42 million. A total of 1.34% of the company’s stock is owned by insiders.
During the past 12 months, Tilray Brands Inc has had a low of $1.50 and a high of $3.40. As of last week, the company has a debt-to-equity ratio of 0.16, a current ratio of 1.63, and a quick ratio of 0.99. The fifty day moving average price for TLRY is $1.8534 and a two-hundred day moving average price translates $2.0283 for the stock.
The latest earnings results from Tilray Brands Inc (NASDAQ: TLRY) was released for Nov, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.07, missing analysts’ expectations of -$0.06 by -0.01. This compares to -$0.10 EPS in the same period last year. The net profit margin was -204.18% and return on equity was -36.49% for TLRY. The company reported revenue of $193.77 million for the quarter, compared to $144.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.44 percent. For the current quarter, analysts expect TLRY to generate $199.71M in revenue.
Tilray Brands Inc(TLRY) Company Profile
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
